Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value CDMO services for the health industry, has appointed Pere Mañé Godina as its new Chief Executive Officer (CEO).

With a career spanning more than 30 years, Godina has held technical and strategic executive positions at leading pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His experience ranges from technical and operational roles to executive positions.

Most recently, Godina played a key role in the industrial transformation of Esteve, positioning its chemical division as a global benchmark. Under his leadership, the company was recognized as CDMO of the Year – Small Molecules at the DCAT 2025 Leadership Awards.

Godina’s arrival brings momentum to Suanfarma’s growth journey. His focus on operational excellence, advanced CDMO capabilities, and strong strategic partnerships will guide the company through its next phase with the following objectives:

• Streamlining industrial operations and integrating new technologies
• Strengthening relationships with global clients and key suppliers
• Accelerating international expansion
• Fostering a culture of innovation and sustainability

“Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team,” said Pere Mañé Godina. “I’m excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients.”